Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Ophthalmic corticosteroidUsed for postoperative ocular pain and inflammation and endogenous anterior uveitisSafety and efficacy comparable to betamethasone 0.1% ophthalmic solution
Durezol Ophthalmic Emulsion: 0.05%
Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery; continue giving 4 times/day for the first 2 weeks of the postoperative period, then administer 2 times daily for 1 week. At the end of the third week, taper dose based on response.
Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery; continue giving 4 times/day for the first 2 weeks of the postoperative period, then administer 2 times daily for 1 week. At the end of the third week, taper dose based on response. In a double-blind trial in pediatric patients (aged 0 to 3 years) who underwent cataract surgery, a similar safety profile was observed in patients who received difluprednate 0.05% (n = 39) compared to those who received prednisolone acetate ophthalmic suspension 1% (n = 40).
Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily for 14 days followed by tapering as clinically indicated.
4 drops/day in each affected eye.
Safety and efficacy have not been established.
No dosage guidelines are available; it appears no dosage adjustment is needed.
NOTE: Care should be taken not to discontinue therapy prematurely. If ocular signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. Intraocular pressure should be monitored after 10 days of therapy, and an ophthalmologic exam should occur after 14 days of therapy.
Difluprednate is administered topically to the eye. Shake well before use.Do not to touch the tip of the dropper to the eye, fingertips, or other surface.Instruct patient on proper instillation of eye solution.When using difluprednate, the patient should not wear contact lenses.
Durezol :- Protect from freezing- Protect from light- Store between 59 to 77 degrees F- Store in carton until time of use
Difluprednate is contraindicated in individuals with glycerin hypersensitivity, hypersensitivity to difluprednate, corticosteroid hypersensitivity, polysorbate 80 hypersensitivity, or any of the other product ingredients (boric acid, castor oil, polysorbate 80, sodium acetate, sodium EDTA, sodium hydroxide).
The use of ocular steroids may prolong the course and exacerbate the severity of ocular infections. Ophthalmic steroid use may result in delayed or impaired wound healing of the eye or cornea, or mask the signs of ocular infection. Difluprednate, as with other ophthalmic corticosteroids, is contraindicated in most cases of viral infection of the cornea and conjunctiva, such as epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella. Difluprednate is also contraindicated in any mycobacterial infection of the eye or fungal infection of ocular structures. Fungal infections of the cornea may develop with long-term ocular application of steroids. Fungal invasion should be evaluated in any persistent corneal ulceration where corticosteroid treatment has been used. Fungal cultures should be taken when appropriate. Corticosteroid therapy can also exacerbate purulent bacterial infections of the eye.
Increased intraocular pressure (intraocular hypertension) is most likely to occur in patients receiving prolonged ophthalmic corticosteroids and in patients with glaucoma. Intraocular pressure elevations are usually greater in eyes with open-angle glaucoma. If difluprednate is used for 10 days or longer, intraocular pressure should be monitored.
Long-term ocular administration of corticosteroids, like difluprednate, for several years has been associated with the formation of posterior subcapsular (PSC) cataracts. Patients with diabetes mellitus appear to be more susceptible to developing PSC cataracts during ocular steroid use. Patients should be monitored for the development of lens opacities during long-term corticosteroid therapy.
In patients with corneal or scleral thinning, administration of topical ophthalmic corticosteroids has caused perforations. Difluprednate should be used with caution in patients with a corneal abrasion.
Patients who wear contact lenses should be aware that Durezol (difluprednate) contains the preservative sorbic acid. As with all ophthalmic preparations containing a preservative, patients should be advised not to wear contact lenses when using Durezol.
Difluprednate is classified as pregnancy category C. Animal studies using subcutaneous doses produced teratogenic and embryotoxic effects. Other corticosteroids have been shown to cause fetal resorptions and malformations. The systemic absorption of difluprednate following ophthalmic administration is minimal; however, according to the manufacturer, because there have been no adequate studies conducted into the safe use of difluprednate in pregnant women, it should only be used when the potential benefits to the mother outweigh possible risks to the fetus.
Difluprednate has not been studied during breast feeding. While the American Academy of Pediatrics does not comment on the use of ophthalmic difluprednate during breast-feeding, it does consider some systemic corticosteroids (prednisone and prednisolone) to be usually compatible with breast-feeding. It is not known whether ophthalmic difluprednate results in sufficient systemic absorption to produce detectable quantities in breast milk; but pharmacokinetic studies indicate that systemic absorption after ophthalmic administration of difluprednate is limited and therefore unlikely that a significant amount of drug would be excreted into breast-milk. To further minimize the amount of drug that reaches the systemic circulation and breast milk, apply pressure over the tear duct by the corner of the eye for 1 minute after ophthalmic administration. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
uveitis / Delayed / 0-10.0ocular hypertension / Delayed / 1.0-10.0keratitis / Delayed / 1.0-10.0visual impairment / Early / 1.0-5.0macular edema / Delayed / 0-1.0
conjunctival hyperemia / Early / 5.0-15.0blepharitis / Early / 5.0-15.0hyperemia / Delayed / 0-15.0corneal edema / Early / 2.0-15.0photophobia / Early / 2.0-15.0blurred vision / Early / 5.0-10.0iritis / Delayed / 1.0-10.0ocular inflammation / Early / 1.0-5.0cataracts / Delayed / Incidence not knownimpaired wound healing / Delayed / Incidence not knownsuperinfection / Delayed / Incidence not knownocular infection / Delayed / Incidence not known
ocular pain / Early / 5.0-15.0ocular irritation / Rapid / 0-10.0xerophthalmia / Early / 2.0-5.0lacrimation / Early / 0-1.0foreign body sensation / Rapid / 0-1.0striae / Delayed / 0-1.0ocular pruritus / Rapid / 0-1.0
There are no drug interactions associated with Difluprednate products.
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the exact mechanism of action for ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. Lipocortins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of the precursor molecule arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids can increase intraocular pressure. The mechanism by which ophthalmic corticosteroids increase intraocular pressure is not clear. Corticosteroids are associated with the presence of extracellular glycosaminoglycans in ocular trabecular cells, which have been hypothesized to increase the resistance of aqueous outflow.
Difluprednate is administered topically to the eye. Difluprednate undergoes deacetylation in vivo to the active metabolite 6 alpha, 9-difluoroprednisolone 17-butyrate (DFB).
Limited systemic absorption of difluprednate occurs following daily administration. In clinical pharmacokinetic studies, DFB levels in blood were below the quantification limit (50 ng/mL) at all time points for all subjects after repeat ocular instillation of 2 drops of difluprednate (0.01% or 0.05%) four times daily for 7 days.